DanielMorgenszternMD
Oncology • Saint Louis, MOAssociate Professor, Washington University School of Medicine, St. Louis, MO.
Dr. Morgensztern is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4921 Parkview Pl
Fl 7
Saint Louis, MO 63110Phone+1 314-747-1171Fax+1 314-362-3192- Is this information wrong?
Education & Training
University of Miami/Jackson Health SystemResidency, Internal Medicine, 1998 - 2001
Tech- Ed Fndn Souza Marques Sch MedClass of 1995
Certifications & Licensure
MO State Medical License 2013 - 2025
CT State Medical License 2010 - 2013- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction Start of enrollment: 2007 Mar 01
- Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Start of enrollment: 2013 Sep 01
- Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 16
- Join now to see all
Publications & Presentations
PubMed
- A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.Riely, G., Smit, E., Ahn, M., Felip, E., Ramalingam, S., Tsao, A., Johnson, M., Gelsomino, F., Esper, R., Nadal, E., Offin, M., Provencio, M., Clarke, J., Hussein, M.,...> ;Future Oncology. 2024 Feb 15
- 1 citationsBiomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-P...> ;Nature Medicine. 2024 Mar 1
- Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.Chirieac, L. R., David S Ettinger, Douglas E Wood, James Stevenson, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian...> ;Journal of the National Comprehensive Cancer Network. 2023 Sep 1
- Join now to see all
Journal Articles
- Recurrent WNT Pathway Alterations Are Frequent in Relapsed Small Cell Lung CancerSaiama N. Waqar, Daniel Morgensztern, Robert S. Fulton, Ramaswamy Govindan, Nature
Lectures
- Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor treatment failure.2019 ASCO Annual Meeting - 6/1/2019
- Multicenter phase II trial of RRx-001 in previously treated SCLC.2019 ASCO Annual Meeting - 6/1/2019
- Yale Cancer Center Evening Oncology Series: Lung CancerYale CME, New Haven, Connecticut - 5/10/2012
Authored Content
- Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small-Cell Lung CancerFebruary 2018
Press Mentions
- Safety and Efficacy of Zimberelimab (AB122) in Combination with Domvanalimab (AB154) and Etrumadenant (AB928) in Patients with Previously Treated Non-Small Cell Lung CancerMarch 10th, 2021
Adding a Vaccine to Immunotherapy in Lung Cancer: Will It Improve Outcomes?March 4th, 2019
Heat Biologics, Inc. (NASDAQ:HTBX) Files an 8-K Regulation FD DisclosureFebruary 28th, 2019- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Barnes-Jewish HospitalSaint Louis, Missouri
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
